Indivior Pharmaceuticals, Inc.
INDV
$33.34
$0.742.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 385.71% | 95.45% | 118.56% | -22.95% | 127.27% |
| Total Depreciation and Amortization | -16.67% | -37.50% | -16.67% | 0.00% | 185.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 0.00% |
| Total Other Non-Cash Items | -174.36% | 0.00% | 208.33% | -40.00% | -77.06% |
| Change in Net Operating Assets | -247.67% | -155.26% | -36.13% | 115.04% | 75.77% |
| Cash from Operations | -1,200.00% | -2,050.00% | 79.55% | 302.70% | 93.61% |
| Capital Expenditure | -50.00% | -185.71% | -325.00% | -150.00% | -300.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -100.00% | -100.00% | -100.00% | 33.33% |
| Cash from Investing | -400.00% | -157.14% | -1,800.00% | -120.00% | -11.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.90% | -300.00% | -- | -300.00% | -4,066.67% |
| Issuance of Common Stock | -- | 0.00% | -- | -50.00% | -- |
| Repurchase of Common Stock | 96.15% | 100.00% | 100.00% | 75.00% | -15.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -100.00% | -- | -- | -- |
| Cash from Financing | -112.50% | 94.12% | 85.71% | 69.64% | 202.56% |
| Foreign Exchange rate Adjustments | -100.00% | -100.00% | -- | -- | -50.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -881.25% | -333.33% | 155.56% | 177.94% | 110.88% |